{{Rsnum
|rsid=522444
|Gene=KIFAP3
|Chromosome=1
|position=170074763
|Orientation=plus
|GMAF=0.152
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=KIFAP3
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 61.9 | 27.0 | 11.1
| HCB | 97.8 | 2.2 | 0.0
| JPT | 100.0 | 0.0 | 0.0
| YRI | 69.4 | 27.4 | 3.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 97.8 | 2.2 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID|19451621|OA=1
}} homozygosity for the favorable allele (CC) associated with a 14 month survival advantage in ALS patients. further analysis (sequence, genotypic, and functional) showed LD between [[rs1541160]] and [[rs522444]] and that favorable alleles correlate with reduced [[KIFAP3]] expression

{{omim
|id=105400
|rsnum=522444
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}